Bavituximab, referred to as TRWH-783, represents an innovative immunotherapy strategy targeting phosphatidylserine (PS). PS is normally a internal lipid present within cell membranes; however, it's commonly displayed https://bookmark-template.com/story28492001/bavituximab-a-novel-method-to-tumor-therapy